AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home BIOCELL Article
PDF (1.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

The Immune-Centric Revolution in the Treatment of Musculoskeletal Disease: Autologous PBMNC and PRP-PBMNC Enriched—A Narrative Review

Andrea De Matthaeis1Laura Rehak2( )Maria Bianchi3Rossana Putzulu3Nicola Piccirillo3,4Giulio Maccauro1
Department of Orthopedics and Traumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Athena Cell Therapy Technologies, Florence, Italy
Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
Show Author Information

Abstract

For over two decades, mesenchymal stem cells (MSCs) have been recognised as the cornerstone of orthobiologic treatments for musculoskeletal diseases. However, clinical evidence increasingly indicates that MSC engraftment in inflamed tissues is minimal and transient, with effects mainly driven by paracrine and immunomodulatory mechanisms induced by macrophage efferocytosis. This evolving paradigm emphasises the immune system as the central orchestrator of tissue repair. Peripheral blood mononuclear cells (PBMNCs) have emerged as potent effectors of regenerative inflammation, mediating apoptotic cell clearance through efferocytosis, facilitating the transition of macrophages from pro-inflammatory (M1) to reparative (M2) phenotypes, and releasing angiogenic and trophic factors that support vascularisation, matrix remodelling, and functional restoration. Clinical studies in critical limb ischemia and diabetic foot provide compelling evidence that autologous PBMNC implantation yields meaningful outcomes in conditions refractory to conventional therapies. Concurrently, platelet-rich plasma (PRP), long regarded as a reservoir of growth factors, is now recognised as a potent recruiter of PBMNCs, where platelet-derived chemokines, such as Monocyte Chemoattractant Protein-1, (MCP-1), Regulated upon Activation, Normal T Cell Expressed and Secreted (RANTES), and Stromal cell-derived factor-1 (SDF-1), establish chemotactic gradients that attract immune cells to injury sites. Neutrophil-depleted, monocyte-enriched PRP formulations demonstrate therapeutic promise in the treatment of osteoarthritis, tendinopathy, and muscle injury. This review consolidates the current scientific rationale and clinical evidence supporting an immune-centric framework, in which PBMNCs, delivered alone or enriched within PRP, constitute a promising next-generation of orthobiologic therapies for musculoskeletal regeneration.

References

【1】
【1】
 
 
BIOCELL

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
De Matthaeis A, Rehak L, Bianchi M, et al. The Immune-Centric Revolution in the Treatment of Musculoskeletal Disease: Autologous PBMNC and PRP-PBMNC Enriched—A Narrative Review. BIOCELL, 2026, 50(5). https://doi.org/10.32604/biocell.2026.073783

283

Views

16

Downloads

0

Crossref

0

Web of Science

1

Scopus

Received: 25 September 2025
Accepted: 31 December 2025
Published: 13 May 2026
© The Author 2026.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.